Broad Late‑Stage Immuno Oncology Pipeline Will Drive Long Term Opportunity

Catalysts

About Summit Therapeutics

Summit Therapeutics is a biopharmaceutical company focused on developing ivonescimab for the treatment of multiple solid tumor cancers.

What are the underlying business or industry changes driving this perspective?

• The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.
• The multiregional HARMONi, HARMONi-3, HARMONi-7 and HARMONi-GI3 programs target large patient groups in non small cell lung cancer and colorectal cancer at a time when checkpoint use is already embedded in treatment standards. Positive outcomes in these settings could directly influence future revenue scale and commercial operating leverage.
• Collaborations with Revolution Medicines, GSK and cooperative groups such as GORTEC extend ivonescimab into RAS mutant tumors, small cell lung cancer and head and neck cancer without Summit funding every trial alone. This structure can limit R&D cash burn relative to the opportunity set and may support future earnings and margin potential if any partnered programs succeed.
• Akeso’s extensive China program, including 10 Phase III trials, 2 existing approvals and over 60,000 treated patients, gives Summit access to a large body of external data and real world use that can inform trial design and regulatory discussions. This may potentially shorten development paths and influence the timing and durability of any future revenue and earnings streams.
• The current cash balance of about US$713.4 million with no debt gives Summit room to fund its late stage pipeline and commercial build out while keeping financing risk contained. This can affect future net margins and earnings sensitivity if ivonescimab generates meaningful sales.

Assumptions

How have these above catalysts been quantified?

• Summit Therapeutics currently has no revenue. Analysts are forecasting revenue to reach $897.3 million by June 2029.
• Analysts are not forecasting that Summit Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Summit Therapeutics's profit margin will increase from 0.0% to the average GB Biotechs industry of 18.9% in 3 years.
• If Summit Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $169.7 million (and earnings per share of $0.19) by about June 2029, up from -$1.2 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $345.0 million in earnings, and the most bearish expecting $-1.1 billion.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 182.1x on those 2029 earnings, up from -9.1x today. This future PE is greater than the current PE for the GB Biotechs industry at 16.7x.
• Analysts expect the number of shares outstanding to grow by 4.48% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.17%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Ivonescimab is still awaiting key regulatory decisions, including the U.S. FDA review of the HARMONi BLA where the agency has already indicated that a statistically significant overall survival benefit is needed, so any shortfall versus regulatory expectations could delay or limit approvals and weigh on potential future revenue and earnings.
• Summit has a single lead asset at the center of a very broad clinical program with at least 15 Phase III trials and multiple combinations. Disappointing efficacy or safety outcomes in any major indication, or weaker than expected overall survival trends relative to strong existing checkpoint standards, could constrain the eventual addressable market and pressure future revenue scale and net margins.
• The company is spending heavily on R&D and commercialization build out, with fourth quarter 2025 non GAAP operating expenses of US$113.3 million and no current product revenue. If key trials or launches are delayed or do not translate into wide adoption, ongoing cash burn could become a headwind for future earnings and may force dilution or more cautious growth plans.
• Summit’s development and commercial thesis relies in part on China generated data and on multiple external collaborations, including Akeso, Revolution Medicines, GSK and cooperative groups. Any change in partner priorities, trial design expectations or regional regulatory requirements, for example around contribution of components or Project Optimus, could slow program execution and affect the timing and durability of future revenue and margin progression.
• Management and analysts highlight a large global market for checkpoint and anti VEGF therapies, but these markets are already highly competitive with entrenched drugs and evolving standards of care. Pricing pressure, payer scrutiny and the need to fund a broader sales footprint beyond the initial EGFR mutant niche could limit achievable pricing power and compress long term net margins and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $28.36 for Summit Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $44.24, and the most bearish reporting a price target of just $9.79.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $897.3 million, earnings will come to $169.7 million, and it would be trading on a PE ratio of 182.1x, assuming you use a discount rate of 7.2%.
• Given the current share price of $14.18, the analyst price target of $28.36 is 50.0% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.